Baidu
map

ANN ONCOL:非转移性胰腺癌化疗后如何选择需进行手术切除的患者

2017-11-08 MedSci MedSci原创

交界性(BL)或局部晚期(LA)胰腺癌患者通常需要先进行化疗后选择合适的患者进行手术切除。ANN ONCOL近期发表了一篇文章,研究化疗后可以进行切除的患者的选择标准。

交界性(BL)或局部晚期(LA)胰腺癌患者通常需要先进行化疗后选择合适的患者进行手术切除。ANN ONCOL近期发表了一篇文章,研究化疗后可以进行切除的患者的选择标准。研究共纳入2002年至2016年间确诊为交界性或局部晚期胰腺癌,接受吉西他滨化疗3-6个月后进行手术的患者。影像学或术中检查发现可以进行根治性切除的患者会接受手术切除治疗。作者回顾性分析了治疗前影响因素和治疗反应,寻找可以改善需进行手术患者选择的标准。研究结果表明,总人群的平均生存时间是18.3个月。61例患者接受手术切除。接受手术切除的患者平均生存时间显着长于未接受切除的手术患者。根据反应评价标准,48%患者出现部分反应,47%患者出现病情稳定,5%患者出现疾病进展。77.8%的患者出现CA19.9反应(下降>50%)。在切除的患者中,术前因素或治疗反应均不能预测生存差异。无CA19.9反应的切除患者生存显着低于有反应的患者。对总人群的多因素分析表明Karnofsky评分、T3-T4、手术切除和CA19.9反应是独立预后因素,而放射反应、BL/LA和CA19.9基线水平对生存无显着影响。文章最后认为,CA19.9反应可

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865192, encodeId=44ce1865192e0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 14 04:10:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819665, encodeId=32a8181966588, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 13 01:10:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080143, encodeId=705f208014334, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 13 15:10:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386310, encodeId=cc9a138631024, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390219, encodeId=734213902194b, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93435, encryptionId=8c36934354a, topicName=转移性胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5002500055, createdName=124986d2m09暂无昵称, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429413, encodeId=6a601429413bc, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
    2018-01-14 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865192, encodeId=44ce1865192e0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 14 04:10:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819665, encodeId=32a8181966588, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 13 01:10:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080143, encodeId=705f208014334, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 13 15:10:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386310, encodeId=cc9a138631024, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390219, encodeId=734213902194b, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93435, encryptionId=8c36934354a, topicName=转移性胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5002500055, createdName=124986d2m09暂无昵称, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429413, encodeId=6a601429413bc, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865192, encodeId=44ce1865192e0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 14 04:10:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819665, encodeId=32a8181966588, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 13 01:10:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080143, encodeId=705f208014334, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 13 15:10:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386310, encodeId=cc9a138631024, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390219, encodeId=734213902194b, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93435, encryptionId=8c36934354a, topicName=转移性胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5002500055, createdName=124986d2m09暂无昵称, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429413, encodeId=6a601429413bc, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865192, encodeId=44ce1865192e0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 14 04:10:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819665, encodeId=32a8181966588, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 13 01:10:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080143, encodeId=705f208014334, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 13 15:10:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386310, encodeId=cc9a138631024, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390219, encodeId=734213902194b, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93435, encryptionId=8c36934354a, topicName=转移性胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5002500055, createdName=124986d2m09暂无昵称, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429413, encodeId=6a601429413bc, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865192, encodeId=44ce1865192e0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 14 04:10:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819665, encodeId=32a8181966588, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 13 01:10:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080143, encodeId=705f208014334, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 13 15:10:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386310, encodeId=cc9a138631024, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390219, encodeId=734213902194b, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93435, encryptionId=8c36934354a, topicName=转移性胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5002500055, createdName=124986d2m09暂无昵称, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429413, encodeId=6a601429413bc, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1865192, encodeId=44ce1865192e0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 14 04:10:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819665, encodeId=32a8181966588, content=<a href='/topic/show?id=b018996931d' target=_blank style='color:#2F92EE;'>#非转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99693, encryptionId=b018996931d, topicName=非转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 13 01:10:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080143, encodeId=705f208014334, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99694, encryptionId=fc8c9969495, topicName=非转移性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 13 15:10:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386310, encodeId=cc9a138631024, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390219, encodeId=734213902194b, content=<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93435, encryptionId=8c36934354a, topicName=转移性胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5002500055, createdName=124986d2m09暂无昵称, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429413, encodeId=6a601429413bc, content=<a href='/topic/show?id=bb015438221' target=_blank style='color:#2F92EE;'>#手术切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54382, encryptionId=bb015438221, topicName=手术切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfdd4195665, createdName=s_pl2009, createdTime=Fri Nov 10 01:10:00 CST 2017, time=2017-11-10, status=1, ipAttribution=)]

相关资讯

Gastroenterology:胰腺癌血管生成机制获揭示

天津医科大学肿瘤医院胰腺肿瘤科郝继辉、任贺课题组独立完成的最新研究成果证实,免疫调节因子IL-35通过细胞浸润,诱导其分泌促血管新生因子,来促进胰腺癌的血管新生。研究解析了胰腺癌血管生成的新机制,进而阐明了胰腺癌对于传统抗血管生成药物治疗无效的原因,为胰腺癌的抗血管新生治疗提供了新的靶点。该研究论文日前发表在国际胃肠病领域排名第一的杂志《Gastroenterology》上。

Eur Radiol:诊断胰腺癌就单单开个磁共振检查单?磁共振弹性成像在诊断胰腺癌中价值!

胰腺导管腺癌是常见的一种胰腺癌的类型,它可以分为4期。一期无残留的肿瘤切除生存时间要大大长于其他时期的导管腺癌,因此做好尽早的发现导管腺癌,对患者有着重要的意义。另外人们又常常不能够尽早的发现导管腺癌,能施行一期无肿瘤残存的手术人数只有5%。所以提高导管腺癌的诊断机制对导管腺癌的治愈有着重要的意义。本研究旨在验证MR弹性成像(MRE)并将其与血清CA19-9在鉴别良恶性胰腺肿块的诊断价值,尤其是胰

CLIN CANCER RES:糖尿病胰腺癌患者免疫缺陷特点

胰腺癌往往到疾病晚期才得以诊断,此时已没有有效的治疗手段。目前,免疫疗法为这一恶性肿瘤的治疗提供了新的希望。免疫治疗在许多类型的肿瘤患者中均有获益,但是胰腺癌患者并无获益。糖尿病和胰腺癌都是源于同一器官异常,糖尿病和胰腺癌有共同发生的倾向。CLIN CANCER RES近期发表了一篇文章,研究糖尿病对胰腺癌患者免疫治疗的影响。

JAMA Oncol:四个基因决定胰腺癌患者的生存期

切除胰腺腺癌的患者出现疾病复发的风险很高,但很少有生物标志物可用于预测患者结果。来自罗切斯特大学医学中心的研究人员就对胰腺癌中4种主要驱动基因的改变以及癌症切除后的患者预后进行了评估。

Sci Rep:循环miRNA-21-5p或是早期胰腺癌诊断的生物标志物

世界范围内胰腺癌(PC)是一种高致命性疾病,其早期阶段常常被误诊。探索新型非侵入性生物标志物必定会使PC患者受益。最近,体液中的循环miRNAs正在成为PC诊断的非侵入性生物标志物。在本研究中,我们首先对21个已发表的miRome谱分析研究进行了全面的稳健的秩聚合(RRA)分析。我们统计确定并临床验证PC患者中的miRNA表达模式。这些miRNAs包括四个上调miRNAs(hsa-miR-21-5

[胰腺癌年会]虞先濬教授畅谈胰腺癌治愈之路

胰腺癌“癌中之王”的称号可能会让很多人闻风丧胆,临床肿瘤专家对胰腺癌的治疗可谓是绞尽脑汁、鞠躬尽瘁。胰腺癌的治疗由原来的单一手术治疗到现在的药物治疗等的出现,给患者带来了更多的选择。2017年10月27日-29日,中国抗癌协会胰腺癌专业委员会年会在天津召开。

Baidu
map
Baidu
map
Baidu
map